Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses

Human Gene Therapy

Volumn 13, Issue 13, 2002, Pages 1571-1581

  Xin, Ke Qin ^a   Ooki, Takaaki ^a   Mizukami, Hiroaki ^b   Hamajima, Kenji ^a   Okudela, Koji ^a   Hashimoto, Kumiko ^a   Kojima, Yoshitsugu ^a   Jounai, Nao ^a   Kumamoto, Yasuko ^a   Sasaki, Shin ^c   Klinman, Dennis ^d   Ozawa, Keiya ^b   Okuda, Kenji ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD8 ANTIGEN; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT DNA; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; VACCINIA; VACCINIA VIRUS; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADMINISTRATION, ORAL; AIDS VACCINES; ANIMALS; DEPENDOVIRUS; GENE PRODUCTS, ENV; GENETIC VECTORS; HIV-1; IMMUNITY, MUCOSAL; MICE; MICE, INBRED BALB C; VACCINES, SYNTHETIC;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; VACCINIA VIRUS;

EID: 0036375003     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340260201662     Document Type: Article

References (45)

1. Humoral and cell-mediated immune response to live recombinant BCG-HIV vaccines
2. Phenotypic analysis of antigen-specific T lymphocytes
3. Dendritic cells and the control of immunity
4. The effects of DNA containing CpG motif on dendritic cells
5. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV- and gp120 SF-2 recombinant vaccines in uninfected volunteers
6. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge
7. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration
8. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: Vector design strategies for improved vaccine efficacy
9. Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine
10. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle
11. rAAV vectors as an AIDS vaccine
12. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
13. Peroral gene therapy of lactose intolerance using an adeno-associated virus vector
14. An oral vaccine against NMDR1 with efficacy in experimental stroke and epilepsy
15. Intestinal antibody responses to oral vaccination in HIV-infected individuals
16. Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors
17. Recombinant adeno-associated virus for muscle directed gene therapy
18. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector
19. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes
20. + T lymphocytes producing tumor necrosis factor a spots in response to peptide antigens
21. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
22. Researchers and regulators reflect on first gene therapy death
23. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
24. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line
25. Site-specific integration by adeno-associated virus
26. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa
27. + T cells from HIV-infected persons
28. In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model
29. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D
30. Induction of protective immunity against pathogenic simian immunodeficiency virus by a foreign receptor-dependent replication of an engineered avirulent virus
31. Live-attenuated HIV vaccines: How safe enough?
32. + hematopoietic progenitor cells: Donor variation and correlation of transgene expression with cellular differentiation
33. Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: Implications for ex vivo im-munotherapy
34. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
35. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors
36. Recombinant rabies virus as potential live-viral vaccines for HIV-1
37. Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse
38. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
39. + T-cell memory following infection with recombinant sindbis and vaccinia viruses
40. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector
41. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to HIV
42. Detection of progeny immune responses after intravenous administration of DNA vaccine to pregnant mice
43. Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols
44. CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: Role of immature dendritic cells